TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24492839

Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation (1000 mg of vitamin C and 235 mg of vitamin E daily for 11 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation
Number of subjects: 54
Study: 22532959

Group type: EXPERIMENTAL
Intervention: 2% glutaraldehyde
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 15.5% ferric sulfate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: formocresol
Number of subjects: 40

Group type: COMPARATOR
Intervention: control group (distilled water for 48 hours)
Number of subjects: 40
Study: 20533969

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) for 6 months
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Spironolactone (SPIRO) for 6 months
Number of subjects: 45
Study: 19839515

Group type: EXPERIMENTAL
Intervention: Surgical procedures in the facial area (group I)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Serious prognosis (group II)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Healthy patients (group III)
Number of subjects: 131
Study: 15805990

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: ICS therapy based on changes in sputum eosinophil counts
Number of subjects: 164

Group type: COMPARATOR
Intervention: ICS
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Sputum eosinophil counts
Number of subjects: 164
Study: 12853535

Group type: EXPERIMENTAL
Intervention: 50% LCTs/50% MCTs 20% lipid emulsion
Number of subjects: 18

Group type: COMPARATOR
Intervention: 20% fat emulsion containing 100% long-chain triglycerides (LCTs)
Number of subjects: 18
Study: 10655924

Group type: EXPERIMENTAL
Intervention: 10% pentastarch in 0.9% saline
Number of subjects: 160

Group type: COMPARATOR
Intervention: Hartmann's solution
Number of subjects: 160
Study: 8866058

Group type: EXPERIMENTAL
Intervention: Reciprocal Teaching
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Text Analysis Training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 46
Study: 1499250

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine rinse, 15 ml solution, twice daily for 30 seconds
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 36
Study: 6092011

Group type: EXPERIMENTAL
Intervention: Single dose prophylaxis with cefotaxime
Number of subjects: 60

Group type: COMPARATOR
Intervention: Multiple dose prophylaxis with cefotaxime for 24 hours
Number of subjects: 60
Study: 31707262

Group type: COMPARATOR
Intervention: WHO growth standards (W-group)
Number of subjects: 15019

Group type: EXPERIMENTAL
Intervention: Shanghai growth standards (S-group)
Number of subjects: 15019
Study: 29624800

Group type: EXPERIMENTAL
Intervention: Degarelix (240 mg initial dose, 480 mg maintenance every 84 days)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Goserelin (3.6 mg initial dose, 10.8 mg maintenance every 84 days)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 234
Study: 27660650

Group type: EXPERIMENTAL
Intervention: modified Yunu-Jian (mYJ)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: mYJ
Number of subjects: 25
Study: 23851424

Group type: EXPERIMENTAL
Intervention: L-carnitine infusion
Number of subjects: 31
Study: 21932141

Group type: EXPERIMENTAL
Intervention: Dragon boat paddling
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group-based walking
Number of subjects: 120
Study: 20698799

Group type: EXPERIMENTAL
Intervention: cyclosporine 0.05%
Number of subjects: 233

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 233
Study: 17537770

Group type: EXPERIMENTAL
Intervention: AHR strategy (n = 102)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Reference strategy (n = 104)
Number of subjects: 210
Study: 15793394

Group type: EXPERIMENTAL
Intervention: KTP laser treatment during staged intact canal wall surgery
Number of subjects: 69

Group type: COMPARATOR
Intervention: No KTP laser treatment during staged intact canal wall surgery
Number of subjects: 69
Study: 11952445

Group type: EXPERIMENTAL
Intervention: Rectally administered diclofenac (Voltaren) 1 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: i.v. opioid (morphine) 0.05 mg/kg
Number of subjects: 50
Study: 9443925

Group type: EXPERIMENTAL
Intervention: 5 mg of alendronate daily
Number of subjects: 1174

Group type: EXPERIMENTAL
Intervention: 2.5 mg of alendronate daily
Number of subjects: 1174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1174

Group type: EXPERIMENTAL
Intervention: Estrogen-progestin
Number of subjects: 1174
Study: 7639416

Group type: EXPERIMENTAL
Intervention: Ibudilast (10 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Elastase (1800 U)
Number of subjects: 41
Study: 2236462

Group type: EXPERIMENTAL
Intervention: Drug treatment for children with pure depression or depression plus an anxiety-related disorder
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo treatment for children with pure depression or depression plus an anxiety-related disorder
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Drug treatment for children with depression plus a concomitant conduct or oppositional disorder
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo treatment for children with depression plus a concomitant conduct or oppositional disorder
Number of subjects: 31
Study: 890229

Group type: EXPERIMENTAL
Intervention: Transverse axial emission tomography (tomographic section view)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional views (without tomographic section view)
Number of subjects: 29
Study: 31821071

Group type: EXPERIMENTAL
Intervention: Increased dose tamoxifen (ID arm; 40 mg daily)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Regular dose tamoxifen (RD arm; 20 mg daily)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Homozygous wild-type (wt/wt) patients (20 mg daily)
Number of subjects: 186
Study: 30244144

Group type: EXPERIMENTAL
Intervention: Subthreshold nanosecond laser (SNL) treatment
Number of subjects: 292

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 292
Study: 26443829

Group type: EXPERIMENTAL
Intervention: Induced hypertension
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no induced hypertension)
Number of subjects: 25
Study: 23695747

Group type: EXPERIMENTAL
Intervention: Bladder symptoms among polio survivors
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Gender differences in bladder symptoms
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Incontinence prevalence
Number of subjects: 272

Group type: COMPARATOR
Intervention: Comparison with background population
Number of subjects: 272
Study: 21558066

Group type: EXPERIMENTAL
Intervention: Magnesium (5 g daily) administered intraoperatively and on days 1 and 2 after operation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Magnesium (5 g daily) in patients undergoing pneumonectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo in patients undergoing pneumonectomy
Number of subjects: 200
Study: 18823363

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment from the start without detoxification
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard out-patient detoxification programme without prophylactic treatment from the start
Number of subjects: 56

Group type: COMPARATOR
Intervention: No specific treatment (5-month follow-up)
Number of subjects: 56
Study: 17003291

Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 12637400

Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 4926

Group type: EXPERIMENTAL
Intervention: Folic acid-iron
Number of subjects: 4926

Group type: EXPERIMENTAL
Intervention: Folic acid-iron-zinc
Number of subjects: 4926

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients
Number of subjects: 4926

Group type: COMPARATOR
Intervention: Vitamin A alone
Number of subjects: 4926
Study: 11056756

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 9176898

Group type: EXPERIMENTAL
Intervention: Treated glaucomatous eyes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal control eyes
Number of subjects: 15
Study: 8252502

Group type: EXPERIMENTAL
Intervention: Goserelin acetate plus flutamide
Number of subjects: 264

Group type: COMPARATOR
Intervention: Bilateral orchiectomy
Number of subjects: 264
Study: 2936956

Group type: EXPERIMENTAL
Intervention: Coronary Angioplasty
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intracoronary Streptokinase
Number of subjects: 56
Study: 30249470

Group type: EXPERIMENTAL
Intervention: Omega 3
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 30088452

Group type: EXPERIMENTAL
Intervention: Combination of chemotherapy plus knockdown or mimicking microRNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antagonist oligonucleotides like antagomiRs or anti-miRs and microRNA mimicking
Number of subjects: 0
Study: 26686359

Group type: EXPERIMENTAL
Intervention: Onion juice (100 mL daily for 8 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 24
Study: 25262636

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 37

Group type: COMPARATOR
Intervention: Continuous perfusion
Number of subjects: 37
Study: 22549092

Group type: EXPERIMENTAL
Intervention: Basiliximab 20 mg
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Basiliximab 40 mg
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 149
Study: 20569714

Group type: EXPERIMENTAL
Intervention: Optimal evidence-based medical therapy (use of all 4 indicated medications)
Number of subjects: 9294

Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs
Number of subjects: 9294

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 9294

Group type: EXPERIMENTAL
Intervention: ACE-Is/ARBs
Number of subjects: 9294

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 9294

Group type: EXPERIMENTAL
Intervention: Optimal evidence-based medical therapy
Number of subjects: 9294
Study: 18390443

Group type: EXPERIMENTAL
Intervention: Quibron SR tablets 300 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Respro-SR pellets filled Capsules 300 mg
Number of subjects: 12
Study: 16206579

Group type: EXPERIMENTAL
Intervention: Preventive load and early administration of antioxidants (Group 2), enterally fed with Berlamine-modular for 5 days before surgery and in the postoperative period.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High oxygen supply values at all stages of surgical treatment (Group 3), optimized infusion therapy and compensated intraoperative blood loss.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Comprehensive approach to preventing ARF (Group 4), prevention of ischemia and reperfusion, optimized blood oxygen-transporting function.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group, no use of aminoglycosides, prevention of hyperglycemia, provision of steady-state hemodynamics.
Number of subjects: 100
Study: 12471316

Group type: EXPERIMENTAL
Intervention: OMNI RPE scale
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Borg RPE scale
Number of subjects: 57
Study: 10594520

Group type: EXPERIMENTAL
Intervention: Insulin (0.15 units/kg, iv) induced hypoglycaemia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GHRH (100 mg, iv) with and without pyridostigmine (120 mg orally)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Spontaneous nocturnal GH secretion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Serum IGF‐I
Number of subjects: 40
Study: 7600433

Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 41

Group type: COMPARATOR
Intervention: SD-Ag (control group)
Number of subjects: 41
Study: 2328558

Group type: EXPERIMENTAL
Intervention: Analgesic agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analgesic plus antihistaminic agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 535832

Group type: EXPERIMENTAL
Intervention: Lithium carbonate therapy
Number of subjects: 0
Study: 30439452

Group type: EXPERIMENTAL
Intervention: Placebo analgesia (PA) condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cold-pain condition
Number of subjects: 0
Study: 28039212

Group type: EXPERIMENTAL
Intervention: Single lead atrial pacing (AAIR)
Number of subjects: 1384

Group type: COMPARATOR
Intervention: Dual chamber pacing (DDDR)
Number of subjects: 1384
Study: 25772806

Group type: EXPERIMENTAL
Intervention: Low-load very high-repetition resistance training (BodyPump™)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 23527358

Group type: EXPERIMENTAL
Intervention: Prehydrated corticocancellous porcine bone (PCPB)
Number of subjects: 37

Group type: COMPARATOR
Intervention: 100% deproteinated particulated bovine bone (DPBB)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Implants placed with adequate primary stability
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Implants placed in residual bone crests greater than 2 mm but less than 4 mm
Number of subjects: 37
Study: 21851642

Group type: EXPERIMENTAL
Intervention: Fixed-combination latanoprost 50 μg/mL and timolol 0.5 mg/mL (LTFC)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Unfixed combination of latanoprost (one drop in the evening) and timolol (one drop in the morning) (LTuFC)
Number of subjects: 125
Study: 18799157

Group type: EXPERIMENTAL
Intervention: Comprehension of numerals and natural language quantifiers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Truth-Value Judgment task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehension of numerals
Number of subjects: 0
Study: 17500381

Group type: EXPERIMENTAL
Intervention: Etanercept therapy
Number of subjects: 0
Study: 15669455

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (20 ml of 2% lidocaine with adrenaline 1 in 200000)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Combined 3-in-1 and sciatic nerve block (50 ml of 1% lignocaine with adrenaline 1 in 200000, using nerve stimulator)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 49

Group type: COMPARATOR
Intervention: Combined 3-in-1 and sciatic nerve block
Number of subjects: 49
Study: 11463596

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (CPAP) treatment for 6 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (untreated OSA patients)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nonapneic snorers (SN)
Number of subjects: 64
Study: 9159445

Group type: EXPERIMENTAL
Intervention: Embryos with multinucleated blastomeres (MNB)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: 2-cell stage embryos with a mononucleated and a binucleated blastomere
Number of subjects: 338

Group type: COMPARATOR
Intervention: 2-cell embryos
Number of subjects: 338

Group type: COMPARATOR
Intervention: 4-cell embryos
Number of subjects: 338
Study: 7910231

Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Nationwide sample
Number of subjects: 15000

Group type: COMPARATOR
Intervention: High Wycombe sample
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Population prevalence of reactions to eight foods
Number of subjects: 15000
Study: 3591793

Group type: EXPERIMENTAL
Intervention: Standard Hemodialysis (HD)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hypertonic Hemodiafiltration (H HDF)
Number of subjects: 11
Study: 31861028

Group type: EXPERIMENTAL
Intervention: Ibuprofen (n=20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paracetamol (n=20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Saline, n=20)
Number of subjects: 60
Study: 30019653

Group type: EXPERIMENTAL
Intervention: Polysialylated erythropoietin (PSA‐EPO), administered subcutaneously, aimed for once monthly administration.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polysialylated deoxyribonuclease I (PSA‐DNase), details on administration not specified.
Number of subjects: 0
Study: 27130143

Group type: EXPERIMENTAL
Intervention: rhEPO (500 IU/kg, n = 366)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo (n = 377)
Number of subjects: 800
Study: 25544167

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave combined with orthopaedic insole
Number of subjects: 153

Group type: COMPARATOR
Intervention: Extracorporeal shock wave
Number of subjects: 153

Group type: COMPARATOR
Intervention: Orthopaedic insole
Number of subjects: 153
Study: 22686498

Group type: EXPERIMENTAL
Intervention: Inguinal sentinel lymphadenectomy (SLNE)
Number of subjects: 105
Study: 20102855

Group type: COMPARATOR
Intervention: Weigh to Stay
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Meal replacements (two meal replacements per day) with Weigh to Stay
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Meal replacements (two meal replacements per day) with Weigh to Stay (intent-to-treat analysis)
Number of subjects: 113
Study: 18072053

Group type: EXPERIMENTAL
Intervention: PillCam SB
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EndoCapsule
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study: 16077050

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 120
Study: 12424547

Group type: COMPARATOR
Intervention: 0 mg/kg caffeine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 mg/kg caffeine (at breakfast)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mg/kg caffeine (at breakfast)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 mg/kg caffeine (60 min after breakfast)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 mg/kg caffeine (after breakfast)
Number of subjects: 30
Study: 10051499

Group type: EXPERIMENTAL
Intervention: Two doses of recombinant vaccine (group 1)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Three doses of recombinant vaccine (group 2)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Three doses of plasma-derived vaccine (group 3)
Number of subjects: 318

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 318
Study: 8635039

Group type: EXPERIMENTAL
Intervention: Metoclopramide (80 mg/m2 iv loading dose followed by 20 mg/m2/hr) with dronabinol 5 mg/m2
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Prochlorperazine (6 mg/m2 intravenous loading dose followed by 1.5 mg/m2/hour) with dronabinol 5 mg/m2
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Metoclopramide (80 mg/m2 iv loading dose followed by 20 mg/m2/hr) without dronabinol
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Prochlorperazine (6 mg/m2 intravenous loading dose followed by 1.5 mg/m2/hour) without dronabinol
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both metoclopramide and prochlorperazine
Number of subjects: 126
Study: 1980697

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 6783059

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Exercise without preliminary treatment
Number of subjects: 17
Study: 30640482

Group type: EXPERIMENTAL
Intervention: CBT + MM (Cognitive Behavioral Therapy + Mindfulness Meditation)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: CBT + PMR (Cognitive Behavioral Therapy + Progressive Muscle Relaxation)
Number of subjects: 404

Group type: COMPARATOR
Intervention: AoC (Assessment-only Control)
Number of subjects: 404
Study: 29157275

Group type: EXPERIMENTAL
Intervention: Combination community-based intervention (CBI)
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 1080
Study: 26017304

Group type: EXPERIMENTAL
Intervention: Pasireotide 40 mg every 28 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pasireotide 40 or 60 mg every 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pasireotide
Number of subjects: 0
Study: 24928359

Group type: EXPERIMENTAL
Intervention: Bone tunnel technique
Number of subjects: 79

Group type: COMPARATOR
Intervention: Tunnel-free technique
Number of subjects: 79
Study: 22847485

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 8-session group format
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison condition (time-matched)
Number of subjects: 0
Study: 19344195

Group type: EXPERIMENTAL
Intervention: Web-based case management program plus usual care
Number of subjects: 77

Group type: COMPARATOR
Intervention: Usual clinic care alone
Number of subjects: 77
Study: 16889931

Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity Amelioration Training (ASAT)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 404
Study: 14872148

Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg/d)
Number of subjects: 12218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12218
Study: 11476288

Group type: EXPERIMENTAL
Intervention: Total homocysteine (tHcy) levels
Number of subjects: 0
Study: 9883785

Group type: EXPERIMENTAL
Intervention: Pro-Self Program (self-care intervention)
Number of subjects: 0
Study: 7978427

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg R 80122
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 mg/kg enoximone
Number of subjects: 20
Study: 2688778

Group type: EXPERIMENTAL
Intervention: 10-day methadone withdrawal programme
Number of subjects: 132

Group type: COMPARATOR
Intervention: 21-day methadone withdrawal programme
Number of subjects: 132
Study: 31898192

Group type: EXPERIMENTAL
Intervention: PAP-NAP
Number of subjects: 139
Study: 30112930

Group type: EXPERIMENTAL
Intervention: Lifitegrast ophthalmic solution 5.0%
Number of subjects: 2464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2464